Francisco Silva - 26 Aug 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role: VP of Research and Development, Director
Signature: /s/ Francisco Silva
Issuer symbol: BRTX
Transactions as of: 26 Aug 2022
Net transactions value: +$5,367
Form type: 4
Filing time: 09 Sep 2022, 18:17:17 UTC
Previous filing: 15 Jun 2022
Next filing: 12 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BRTX	Common Stock	Sale	$13,410	-3,958	-2.4%	$3.39	158,156	26 Aug 2022	Direct	F1, F2
transaction	BRTX	Common Stock	Purchase	$8,710	+2,600	+1.6%	$3.35	160,756	26 Aug 2022	Direct	F2
transaction	BRTX	Common Stock	Purchase	$9,048	+2,816	+1.8%	$3.21	163,572	29 Aug 2022	Direct	F2, F3
transaction	BRTX	Common Stock	Purchase	$1,019	+307	+2.6%	$3.32	12,136	29 Aug 2022	IRA	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BRTX	Stock Option						1	26 Aug 2022	Common Stock	1	$3000.00	Direct	F5
holding	BRTX	Stock Option						1	26 Aug 2022	Common Stock	1	$3000.00	Direct	F5
holding	BRTX	Stock Option						3	26 Aug 2022	Common Stock	3	$3000.00	Direct	F5
holding	BRTX	Stock Option						1	26 Aug 2022	Common Stock	1	$3000.00	Direct
holding	BRTX	Stock Option						9	26 Aug 2022	Common Stock	9	$3000.00	Direct	F5
holding	BRTX	Stock Option						6	26 Aug 2022	Common Stock	6	$3000.00	Direct	F5
holding	BRTX	Stock Option						15	26 Aug 2022	Common Stock	15	$3000.00	Direct	F5
holding	BRTX	Stock Option						20	26 Aug 2022	Common Stock	20	$3000.00	Direct	F5
holding	BRTX	Stock Option						25	26 Aug 2022	Common Stock	25	$3000.00	Direct	F5
holding	BRTX	Stock Option						293,479	26 Aug 2022	Common Stock	293,479	$13.50	Direct	F6
holding	BRTX	Stock Option						42,059	26 Aug 2022	Common Stock	42,059	$13.50	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents transaction inadvertently effected by the reporting person. This transaction was executed in multiple trades at prices ranging from $3.33 to $3.45 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
F2	Includes 105,081 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,036 shares on each of September 18, 2022, November 18, 2022 and January 18, 2023, 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F3	This transaction was executed in multiple trades at prices ranging from $3.21 to $3.2159 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
F4	This transaction was executed in multiple trades at prices ranging from $3.28 to $3.35 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
F5	The option is currently exercisable.
F6	The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F7	The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.